CRSP CRISPR Therapeutics AG - Common Shares
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 3, 2026
$55.43
· of 52w range
· above low
· to high
$44.1252w low
$78.4852w high
Market Cap (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Revenue (TTM)
$13M
your badges
52W Range
$44–$78
Analyst Rating
BUY
Price Target
$88
P/E
-11.8
ROE
-26.1%
Net Profit Margin
-3368.7%
Your badge strip is empty — pin a metric anywhere on this page.
CRSP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$55.43
Market Cap (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Revenue (TTM)
$13M
ROE (TTM)
-26.1%
52W Range
$44–$78
CRSP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About CRISPR Therapeutics AG - Common Shares Company overview from Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
countryCH
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$4M2016-12-31 → 2025-12-31
EPS$-6.472017-12-31 → 2025-12-31
Free Cash Flow$-346M2016-12-31 → 2025-12-31
Net margin-3368.7%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CRSP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -11.85Y avg ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 400.15Y avg ≈841.4 | ≈841.4 | · | · | |
| P/B (MRQ) | 3.15Y avg ≈2.2 | ≈2.2 | · | · | |
| Price / FCF (TTM) | -14.45Y avg ≈-9.9 | ≈-9.9 | · | · | |
| Price / Cash Flow (TTM) | -14.55Y avg ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book | 2.85Y avg ≈2.2 | ≈2.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CRSP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -3990.0%5Y avg ≈-15278.7% | ≈-15278.7% | · | · | |
| EBITDA Margin (TTM) | -3850.4%5Y avg ≈-14752.4% | ≈-14752.4% | · | · | |
| Pretax Margin (TTM) | -3346.1%5Y avg ≈-14347.2% | ≈-14347.2% | · | · | |
| Net Profit Margin (TTM) | -3368.7%5Y avg ≈-14364.6% | ≈-14364.6% | · | · | |
| ROA (TTM) | -19.3%5Y avg ≈-11.7% | ≈-11.7% | -40.4% | Top tier | |
| ROE (TTM) | -26.1%5Y avg ≈-15.6% | ≈-15.6% | -46.3% | Top tier | |
| ROIC | -34.8%5Y avg ≈-18.3% | ≈-18.3% | -57.7% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CRSP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 17.85Y avg ≈17.7 | ≈17.7 | 7.8 | Strong liquidity | |
| Quick Ratio | 13.25Y avg ≈17.5 | ≈17.5 | 6.5 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CRSP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -90.6%5Y avg ≈31552.0% | ≈31552.0% | · | · | |
| Revenue CAGR 3Y | 43.1%5Y avg ≈226.6% | ≈226.6% | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | CRSP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.1 | ≈0.1 | · | · | |
| Receivables Turnover | 0.35Y avg ≈817.5 | ≈817.5 | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.09%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.94 | $-1.22 | 23.0% |
| March 31, 2026 | $-1.28 | $-1.25 | -2.5% | |
| Dec. 31, 2025 | $-1.37 | $-1.18 | -16.4% | |
| Sept. 30, 2025 | $-1.17 | $-1.29 | 9.0% | |
| June 30, 2025 | $-1.29 | $-1.45 | 11.2% | |
| March 31, 2025 | $-1.58 | $-1.28 | -23.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.04 | $22.53 | $23.52 | $23.89 | $31.17 | $22.52 | $15.46 | $7.56 | $4.63 | $5.86 | · | |
| Revenue / Share | $0.04 | $0.44 | $4.69 | $0.02 | $11.38 | $0.01 | $5.09 | · | · | · | · | |
| Cash Flow / Share | $-3.84 | $-1.69 | $-3.29 | $-6.38 | $6.70 | $-3.61 | $1.00 | · | · | · | · | |
| Cash / Share | $3.62 | $3.48 | $4.87 | $2.70 | $11.99 | $15.81 | $15.53 | $8.81 | $5.91 | $7.94 | · | |
| EPS (TTM) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-7.05 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.07 | $18.83 | · | $20.41 | $19.36 | $21.18 | · | $22.73 | $23.29 | $24.56 | · | $21.75 | $22.88 | $23.52 | · | $24.97 | |
| Revenue / Share | $0.11 | $0.02 | · | $0.01 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.00 | $0.89 | $1.27 | · | $0.00 | |
| Cash Flow / Share | · | $-1.13 | · | · | · | $-0.63 | · | · | · | $1.34 | · | · | · | $0.11 | · | · | |
| Cash / Share | $3.01 | $4.39 | · | $3.05 | $2.19 | $2.72 | · | $2.64 | $5.70 | $8.34 | · | $6.64 | $5.60 | $4.37 | · | $6.32 | |
| EPS (TTM) | $-4.71 | $-6.17 | · | $-5.56 | $-5.40 | $-4.49 | · | $-2.81 | $-3.21 | $-2.70 | · | $-4.46 | $-5.29 | $-6.71 | · | $-8.52 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $38M | $38M | $38M | · | $203M | $202M | $272M | · | $170M | $170M | $100M | · | $14M | |
| Net Income TTM | $-451M | $-569M | · | $-488M | $-468M | $-386M | · | $-240M | $-266M | $-217M | · | $-354M | $-416M | $-524M | · | $-681M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -11.6 | -7.7 | · | -11.7 | -9.0 | -7.6 | · | -16.7 | -16.8 | -25.2 | · | -10.2 | -10.6 | -6.7 | · | -7.7 | |
| P/S | 393.7 | 1117.5 | · | 158.7 | 113.0 | 78.0 | · | 19.8 | 22.7 | 21.3 | · | 21.2 | 26.2 | 35.6 | · | 362.9 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| Earnings Yield | -8.6% | -13.0% | · | -8.6% | -11.1% | -13.2% | · | -6.0% | -5.9% | -4.0% | · | -9.8% | -9.4% | -14.8% | · | -13.0% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M |
| Operating Margin % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M |
| Diluted EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M |
Institutional owners (13F) 572 filers · $4.3B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
572
Value held
$4.3B
New positions
82
Exited positions
47
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 82 (-14 vs prior Q) | 47 (-13 vs prior Q) | 158 (-19 vs prior Q) | 157 (+29 vs prior Q) | -2.0M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARK Investment Management LLC | $515,999,631 | 9,460,939 | 12.01% | Shares |
| BlackRock, Inc. | $455,353,197 | 8,348,977 | 10.60% | Shares |
| Orbis Allan Gray Ltd | $297,197,241 | 5,449,161 | 6.92% | Shares |
| Capital World Investors | $259,039,094 | 4,749,525 | 6.03% | Shares |
| STATE STREET CORP | $235,703,664 | 4,321,666 | 5.49% | Shares |
| GSK plc | $175,652,997 | 3,220,627 | 4.09% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $136,919,043 | 2,509,915 | 3.19% | Shares |
| VANGUARD GROUP INC | $118,954,581 | 2,268,394 | 2.77% | Shares |
| SR One Capital Management, LP | $111,194,134 | 2,038,763 | 2.59% | Shares |
| TWO SIGMA INVESTMENTS, LP | $108,459,389 | 1,988,621 | 2.53% | Shares |
| FMR LLC | $104,089,735 | 1,908,503 | 2.42% | Shares |
| Sumitomo Mitsui Trust Group, Inc. | $93,848,832 | 1,720,734 | 2.19% | Shares |
| Amova Asset Management Americas, Inc. | $93,762,487 | 1,720,097 | 2.18% | Shares |
| EcoR1 Capital, LLC | $75,771,113 | 1,389,276 | 1.76% | Shares |
| UBS Group AG | $71,856,395 | 1,317,499 | 1.67% | Shares |
| Capital International Investors | $69,178,918 | 1,268,407 | 1.61% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $64,457,935 | 1,181,847 | 1.50% | Shares |
| BANK OF AMERICA CORP /DE/ | $62,999,405 | 1,155,105 | 1.47% | Shares |
| NEA Management Company, LLC | $57,734,408 | 1,058,570 | 1.34% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57,694,430 | 1,057,837 | 1.34% | Shares |
| D. E. Shaw & Co., Inc. | $48,748,506 | 893,812 | 1.13% | Shares |
| MORGAN STANLEY | $47,992,455 | 879,949 | 1.12% | Shares |
| NORTHERN TRUST CORP | $47,072,983 | 863,091 | 1.10% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35,380,807 | 648,713 | 0.82% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $31,089,982 | 570,040 | 0.72% | Shares |
| CITADEL ADVISORS LLC | $25,404,514 | 465,796 | 0.59% | Shares |
| JPMORGAN CHASE & CO | $24,569,275 | 431,669 | 0.57% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23,298,288 | 427,178 | 0.54% | Shares |
| MILLENNIUM MANAGEMENT LLC | $20,836,025 | 382,032 | 0.49% | Shares |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20,833,789 | 381,991 | 0.49% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18,456,336 | 338,400 | 0.43% | Put option |
| Bank of New York Mellon Corp | $17,821,531 | 326,761 | 0.41% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17,763,678 | 325,700 | 0.41% | Call option |
| Logos Global Management LP | $16,362,000 | 300,000 | 0.38% | Shares |
| CITADEL ADVISORS LLC | $15,822,054 | 290,100 | 0.37% | Put option |
| Squarepoint Ops LLC | $15,641,472 | 286,789 | 0.36% | Shares |
| Jump Financial, LLC | $15,159,502 | 277,952 | 0.35% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $15,034,803 | 275,375 | 0.35% | Shares |
| GOLDMAN SACHS GROUP INC | $14,855,182 | 272,372 | 0.35% | Shares |
| NORGES BANK | $14,767,032 | 270,756 | 0.34% | Shares |
| WELLS FARGO & COMPANY/MN | $14,353,246 | 263,169 | 0.33% | Shares |
| CITADEL ADVISORS LLC | $13,973,148 | 256,200 | 0.33% | Call option |
| AMERIPRISE FINANCIAL INC | $13,669,977 | 250,614 | 0.32% | Shares |
| Vestmark Advisory Solutions, Inc. | $13,213,188 | 242,266 | 0.31% | Shares |
| RAYMOND JAMES FINANCIAL INC | $12,652,626 | 231,988 | 0.29% | Shares |
| JANE STREET GROUP, LLC | $12,566,016 | 230,400 | 0.29% | Call option |
| PEAK6 LLC | $11,633,382 | 213,300 | 0.27% | Put option |
| Nuveen, LLC | $11,076,474 | 203,089 | 0.26% | Shares |
| ROYAL BANK OF CANADA | $9,438,000 | 173,045 | 0.22% | Shares |
| Marex Group Ltd | $9,303,652 | 170,584 | 0.22% | Shares |
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 filings | Feb. 16, 2021 | · | Initial filing | · | SEC |
| GlaxoSmithKline plc ×5 filings | July 10, 2020 | · | Initial filing | · | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 filings | Feb. 4, 2020 | · | Initial filing | · | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 filings | June 7, 2019 | · | Initial filing | · | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 filings | Feb. 8, 2018 | · | Initial filing | · | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 filings | Jan. 16, 2018 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 32 insiders · 12 officers · 16 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | March 20, 2026 M | 255,501 | 0 | 9 | $-10,756,932 |
| Brendan Smith | Chief Financial Officer | Feb. 18, 2023 M | 5,072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | March 11, 2021 M | 1,891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | March 20, 2025 M | 10,544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | Aug. 16, 2022 A | 26,797 | 0 | 0 | $0 |
| James R. Kasinger | General Counsel and Secretary | Sept. 22, 2026 M | 94,784 | 0 | 6 | $-1,272,398 |
| Naimish Patel | Chief Medical Officer | May 29, 2026 A | 19,357 | 1 | 2 | $-312,892 |
| Phuong Khanh Morrow | Chief Medical Officer | Oct. 13, 2023 A | 4,411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | Dec. 3, 2021 M | 52,364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | Jan. 16, 2018 M | 25,204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | June 15, 2017 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | Oct. 24, 2016 C | 505,617 | 0 | 0 | $0 |
| Ali Behbahani | Director | Sept. 17, 2026 M | 16,637 | 0 | 1 | $-780,934 |
| Christian Rommel | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Harold Edward Fleming | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Douglas A Treco | Director | June 5, 2026 A | 22,000 | 0 | 0 | $0 |
| Briggs Morrison | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Katherine A High | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| John Greene | Director | June 5, 2026 A | 7,000 | 0 | 0 | $0 |
| Simeon George | Director | June 5, 2026 A | 1,730,179 | 0 | 0 | $0 |
| Maria Fardis | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Sandesh Mahatme | Director | June 5, 2026 A | · | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Director | June 9, 2022 A | 148,831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Director | Nov. 19, 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Director | Dec. 18, 2018 S | 1,171,268 | 0 | 0 | $0 |
| Thomas Woiwode | Director | June 15, 2018 A | 640,014 | 0 | 0 | $0 |
| Anthony N Coles | Director | May 31, 2017 A | 70,000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% owner | Dec. 4, 2017 S | 3,722,534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% owner | Oct. 24, 2016 C | 744,380 | 0 | 0 | $0 |
| GSK plc | 10% owner | Oct. 24, 2016 C | 3,220,627 | 0 | 0 | $0 |
| Raju Prasad | · | Aug. 7, 2026 G | 14,815 | 0 | 10 | $-5,100,841 |
| Rodger Novak | · | June 30, 2021 S | 573,007 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 27 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.53% | 22,018 NS | July 31, 2026 | N-PORT |
| IDNA · iShares Trust | 1.46% | 71,206 SH | Sept. 11, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.66% | 68,253 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.36% | 6,830 SH | Oct. 2, 2026 | Daily |
| IBB · iShares Trust | 0.35% | 685,566 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70,696 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.16% | 2,381,008 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536,446 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.14% | 44,639 NS | July 31, 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.11% | 6,887 SH | Oct. 2, 2026 | Daily |
| ESML · iShares Trust | 0.06% | 34,534 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1,106,455 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.04% | 5,543 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.04% | 115,267 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13,170 SH | Aug. 19, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.04% | 1,727 SH | Oct. 2, 2026 | Daily |
| XT · iShares Trust | 0.03% | 21,859 SH | Sept. 11, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7,774 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20,627 SH | Aug. 19, 2026 | Daily |
| IYY · iShares Trust | 0.01% | 4,231 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.01% | 128,500 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.01% | 25,737 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 75,392 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 760,375 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 4,191 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 20,690 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 58,519 SH | Sept. 11, 2026 | Daily |
CRSP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 28 analysts
BUY
Median target
$80.00
+44.3%
6 21.4%
Strong Buy
11 39.3%
Buy
11 39.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
18 analysts · 2026-10-03Mean target $87.56 +58.0%
Now
Current price $55.43
Low$44.00
Mean$87.56
High$291.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Nasdaq · 3 weeks, 1 day ago
Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
Yahoo Finance · 2 months, 2 weeks ago
2 Beaten-Down Stocks With Massive Upside Potential
Nasdaq · 2 months, 3 weeks ago
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Yahoo Finance · 3 months, 3 weeks ago
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Nasdaq · 4 months ago
Mega-Cap Growth Leadership or Small-Cap Growth Potential? VUG vs. VBK
Nasdaq · 4 months ago
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
Yahoo Finance · 4 months, 2 weeks ago
Notable ETF Outflow Detected - ARKK, CRSP, TEM, HOOD
Nasdaq · 5 months, 2 weeks ago
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area
Nasdaq · 5 months, 3 weeks ago
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Nasdaq · 5 months, 3 weeks ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 3, 2026